Integrated DeepTech Healthcare Group
Turning scientific innovation
into scalable business
Innovative SME and integrated industrial group in healthcare, founded in 2016 in Trieste, Italy.
Why Biovalley
Four elements that define our unique position in the European healthcare landscape.
Proven Track Record
Founder Diego Bravar already built and sold TBS Group for €100M (2017), later revalued at €1 billion (2022).
Dual Growth Model
We combine the solidity of operational SMEs with the disruptive power of high-potential Deep Tech innovation.
Research Ecosystem
Trieste: researcher density 4× the EU/USA average (37.1 per 1,000 residents). A unique scientific hub in Europe.
IPO Target 2026
Listing planned on Euronext Growth Paris in 2026, with an international growth plan.
The Group
An integrated industrial group in healthcare
Biovalley Investments Partner SpA is an innovative SME combining the solidity of operational companies with the disruptive power of Deep Tech innovation in the healthcare sector.
Founded in 2016 in Trieste, it operates through two Business Units — BioTech & Pharma and BioICT — with a portfolio of companies active in pharmaceuticals, robotics, medical informatics and artificial intelligence.
Our storyPerformance by the Numbers
Partners & Clients
IPO Target 2026
Interested in investing in the future of healthcare?
Listing planned on Euronext Growth Paris in 2026. The European healthcare market is worth €1.650 trillion, with the digital health segment growing at 18–23% per year.
Investor Relations